PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-4.18%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
0.97%
Cost growth of 0.97% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
-13.34%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-9.55%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
10.80%
R&D change of 10.80% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
9.35%
G&A change of 9.35% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
57.72%
Marketing expense change of 57.72% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
247.43%
Other expenses change of 247.43% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
19.77%
Operating expenses change of 19.77% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
7.27%
Total costs change of 7.27% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-14.84%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
34.91%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.90%. Jim Chanos would check for overinvestment.
-72.81%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
79.69%
Margin change of 79.69% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-340.87%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-351.38%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-102.93%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-152.83%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-155.14%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-180.21%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-148.50%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-150.62%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-145.28%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-145.28%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
0.27%
Share count change of 0.27% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
-0.36%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate strategy.